对《具有连续终点的序贯设计无效性停止边界的最优性准则》的勘误
Correction to: Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
作者信息
Li Xieran, Herrmann Carolin, Rauch Geraldine
机构信息
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology, Charitéplatz 1, 10117, Berlin, Germany.
Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Germany.
出版信息
BMC Med Res Methodol. 2020 Nov 25;20(1):280. doi: 10.1186/s12874-020-01161-1.
Abstract
An amendment to this paper has been published and can be accessed via the original article.
摘要
本文的一篇修正已发表，可通过原始文章获取。
相似文献
1
Correction to: Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
BMC Med Res Methodol. 2020 Nov 25;20(1):280. doi: 10.1186/s12874-020-01161-1.
2
Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
BMC Med Res Methodol. 2020 Nov 5;20(1):274. doi: 10.1186/s12874-020-01141-5.
3
Design and monitoring of multi-arm multi-stage clinical trials.
Biometrics. 2017 Dec;73(4):1289-1299. doi: 10.1111/biom.12687. Epub 2017 Mar 27.
4
Alternative views on setting clinical trial futility criteria.
J Biopharm Stat. 2014;24(5):976-93. doi: 10.1080/10543406.2014.932285.
5
Interim futility analysis with intermediate endpoints.
Clin Trials. 2008;5(1):14-22. doi: 10.1177/1740774507086648.
6
Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
Biom J. 2017 Jul;59(4):703-731. doi: 10.1002/bimj.201600026. Epub 2016 Oct 19.
7
A Bayesian sequential design with binary outcome.
Pharm Stat. 2017 May;16(3):192-200. doi: 10.1002/pst.1805. Epub 2017 Mar 2.
8
Reducing sample sizes in genome scans: group sequential study designs with futility stops.
Genet Epidemiol. 2003 Dec;25(4):339-49. doi: 10.1002/gepi.10265.
9
Optimal adaptive sequential designs for crossover bioequivalence studies.
Pharm Stat. 2016 Jan-Feb;15(1):15-27. doi: 10.1002/pst.1721. Epub 2015 Nov 5.
10
Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Clin Trials. 2009 Dec;6(6):565-73. doi: 10.1177/1740774509350327. Epub 2009 Nov 23.
引用本文的文献
1
Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.
Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07714-6.
本文引用的文献
1
Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
BMC Med Res Methodol. 2020 Nov 5;20(1):274. doi: 10.1186/s12874-020-01141-5.
Zotero 插件